鲁索利替尼
骨髓纤维化
医学
贾纳斯激酶
Janus激酶2
Janus激酶抑制剂
内科学
肿瘤科
骨髓
受体
作者
Claire Harrison,Jean‐Jacques Kiladjian,Haifa Kathrin Al‐Ali,Heinz Gisslinger,Roger J. Waltzman,Viktoriya Stalbovskaya,Mari McQuitty,Deborah Hunter,R. H. Levy,Laurent Knoops,Francisco Cervantes,Alessandro M. Vannucchi,Tiziano Barbui,Giovanni Barosi
标识
DOI：10.1056/nejmoa1110556
摘要
Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
鸣笛
CAOHOU
昏睡的蟠桃
ED
热心市民小红花
SYLH
pluto
Leo
柯一一
彭于彦祖
科研01
eric888
Billy
CR7
从容芮
MchemG
shinysparrow
iNk
眯眯眼的衬衫
Kuga
皖公网安备34019202002308
